雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效比较--附40例分析

目的 :比较雷贝拉唑三联疗法与奥美拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡的疗效。方法 :将幽门螺杆菌阳性的消化性溃疡 85例分为两组 :治疗组 (雷贝拉唑三联疗法组 ) 4 0例 ,以雷贝拉唑 10mg、阿莫西林 10 0 0mg及甲硝唑 4 0 0mg每日 2次口服 ,治疗 1周后单独服用雷贝拉唑 10mg ,连服 7日 ;对照组 (奥美拉唑三联疗法组 ) 4 5例 :以奥美拉唑 10mg、阿莫西林 10 0 0mg及甲硝唑 4 0 0mg ,每日 2次口服 ,治疗 1周后单独服用奥美拉唑 10mg ,连服 7日。治疗期间每周门诊随诊 ,记录临床症状改善情况 ,用药结束 1个月后复查胃镜并检测幽门螺杆菌结果。结果 :治疗组和对照组治疗 1日的临床症状缓解率分别为 83%、 6 2 % ,差异有统计学意义 (P <0 0 5 ) ;1周后的症状缓解率均为 98%。治疗组和对照组的溃疡愈合率分别为 93%和 76 % ,差异有统计学意义 (P <0 0 5 ) ;治疗组和对照组的总有效率分别为 98%和 96 % ,差异无统计学意义 (P >0 0 5 )。治疗组和对照组的幽门螺杆菌根除率分别为 88%和 78% ,差异无统计学意义 (P >0 0 5 )。结论 :两组方案均能有效治疗消化性溃疡和缓解临床症状 ,并能有效地根除幽门螺杆菌。但雷贝拉唑三联疗法在快速改善临床症状和促进溃疡愈合方面优于奥美拉唑三联疗法。

Efficacy of rabeprazole-based versus omeprazole-based triple therapy on Helicobacter pylori positive peptic ulcer

Objective:To compare the efficacy of rabeprazole-based and omeprazole-based triple therapy in the treatment ofHelicobacter pylori(H pylori)-positive peptic ulcer. Methods: Eighty-five patients with H pylori positive peptic ulcers were randomized into two groups: the 1 st group treated with rabeprazole 10 mg bid(rabeprazole-group n=40 )and the 2 nd group treated with omeprazole 20 mg bid(omeprazole-group n=45) for 1 week, all patients were given amoxicillin 1 g bid and metronidazole 400 mg for one week after. Clinical symptoms were observed and recorded weekly. One month after treatment, the eradication rate ofH pylori and the healing rate of peptic ulcer were evaluated according to result of repeated endoscopy. Results: The relief rate for clinical symptoms in rabeprazole-group and omeprazole-group was 83% and 62% respectively at one day finishing regimen (P<0.05). The relief rate for clinical symptoms in both groups was 98% and 98% respectively at one week finishing regimen (P>0.05), the ulcer healing rate in both groups was 93% and 76%(P<0.05), the global effective rate in both groups was 98% and 96% respectively (P>0.05).and theH pylori eradication rate in both groups was 88% and 78% respectively (P>0.05). Conclusion: Both regimens are effective for curing peptic ulcer, relieving symptoms, and for eradicatingH pylor. Rabeprazole-based triple therapy is superior to omeprazole-based triple therapy in improving symptoms and curing ulcers.